East Kent Hospitals University NHS Foundation Trust | Kent and Canterbury Hospital - Research and Innovation Department

Research site

(Unclaimed)

Location

Ethelbert Road, Canterbury, Kent, England

Site insights

Top conditions

Top treatments

Idelalisib

Cyclophosphamide

Polatuzumab

Prednisone

Bendamustine

Doxorubicin

Pembrolizumab

Chlorambucil

R-CHP

Ciclesonide

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 29 total trials

A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (POLARIX)

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting

Diffuse Large B-Cell Lymphoma

Drug: Vincristine Placebo

Drug: Polatuzumab vedotin Placebo

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

To compare efficacy between zanubrutinib versus bendamustine and rituximab in patients with previously untreated CLL/SLL, as measured by progression...

Active, not recruiting

Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia

Drug: Rituximab

Drug: Venetoclax

An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma

The purpose of this study is to compare the efficacy and safety of glofitamab in combination with polatuzumab vedotin plus rituximab, cyclophosphamid...

Enrolling

Large B-Cell Lymphoma

Drug: Rituximab

Drug: Glofitamab

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

This is a Phase 3 trial to evaluate the BP-lowering effect of lorundrostat (an aldosterone synthase inhibitor) in subjects with uncontrolled and resi...

Active, not recruiting

Hypertension

Drug: Placebo

Drug: lorundrostat Dose 2

PAKT: AZD5363 in Combination With Paclitaxel in Triple-Negative Advanced or Metastatic Breast Cancer

PAKT was an investigator-led, placebo-controlled, randomized phase II trial performed in 42 academic medical centers in the United Kindom, South Kore...

Active, not recruiting

Metastatic Breast Cancer

Drug: AZD5363

Drug: Paclitaxel

PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V (PROTECT-V)

COVID-19 (SARS-CoV2 virus) was declared a global pandemic by the WHO on 11th March 2020. Currently there are no drugs proven to prevent COVID-19 or t...

Enrolling

Covid19

Drug: Placebo

Drug: Sotrovimab

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)

Waldenström's macroglobulinaemia (WM) is a rare type of slow growing lymphoma. It develops when white blood cells grow abnormally.Typically a disease...

Enrolling

Waldenstrom Macroglobulinemia

Drug: Rituximab, ibrutinib

Drug: Dexamethasone, cyclophosphamide, rituximab

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is in...

Enrolling

Follicular Lymphoma (FL)

Drug: Lenalidomide

Drug: Epcoritamab